Medable Discusses Future of Digital Trials on Health Technology Research Panel at the American Heart Association’s Health Tech & Innovation Summit 2019
– Driving the advancement of innovative technologies to accelerate cardiovascular therapeutic and outcomes research
PALO ALTO, Calif.–(BUSINESS WIRE)–Medable Inc., a leading provider of a digital trials platform that connects patients, sites and clinical trial teams, today announced its participation at the American Heart Association (AHA) Health Tech & Innovation Summit on November 16-18, in Philadelphia, Pennsylvania. The conference was designed to increase collaboration between leaders in clinical outcomes and health technology and discusses how technology can measurably improve health outcomes.
Dr. Michelle Longmire, CEO & co-founder at Medable, was selected to speak on the Health Technology Research panel at the Health Innovation Pavilion, where she discussed how mobile-first, patient-centric digital trials can advance cardiovascular therapeutic and outcomes research. Moderated by Dr. Eric Peterson, the Fred Cobb Distinguished Professor of Medicine in the Division of Cardiology at Duke University School of Medicine, the panelists also discussed new digital therapeutics and how clinical research designs adapt to the emergence of newer technologies such as artificial intelligence and machine learning.
“Earlier this year, we joined the AHA’s Center for Health Technology and Innovation’s Innovators Network, where we are developing the Human Heart Digitome, expected to be the largest real-world database to increase our understanding and treatment of cardiovascular disease. Patient data in the registry will not only be used in research and clinical trials but will be analyzed with Medable’s predictive analytics tools to help physicians identify at-risk patients and improve outcomes,” said Dr. Michelle Longmire, CEO & co-founder, Medable.
“Using mobile health tech & digitally-enabled trials, we have been able to increase data sets by screening much larger populations, decrease clinical research time and cost for life sciences companies,” added Jena Daniels, Director of Research at Medable. “As part of the AHA network, it was great to speak with and meet other innovative and scalable solutions through advanced technology in the treatment and prevention of cardiovascular disease.”
About Medable
Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Medable is on a mission to get effective therapies to patients faster by dramatically reducing the time from therapeutic development to market realization with digital data capture and real-time analytics that remove the complexities of clinical research to dramatically reduce trial timelines. Medable is pioneering a new category of life science technologies that replace the stagnant and siloed data of traditional ePRO, eCOA, EDC, and eSource with an intelligent and unified end-to-end (E2E) platform for clinical trial execution. Medable’s end-to-end digital trials platform allows patients, healthcare providers, clinical research organizations and pharmaceutical sponsors to work together as a connected and empowered team in clinical trials and research.
For more information, visit www.medable.com and follow Medable on Twitter: @Medableinc
Contacts
Investors
Medable
investors@medable.com
Media
Letitia Rodley
Media@medable.com
